NCT04596150 is a Phase 2 clinical trial of CX-2009 in Neoplasms, sponsored by CytomX Therapeutics.

Who is sponsoring NCT04596150?

NCT04596150 is sponsored by CytomX Therapeutics.

What drugs are being tested in NCT04596150?

Interventions in NCT04596150: CX-2009, CX-072.

What condition does NCT04596150 study?

NCT04596150 studies Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative.

Is NCT04596150 still recruiting?

NCT04596150 is currently completed. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT04596150

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Completed Phase 2 Last updated 23 January 2024

What this trial tests

Phase 2 trial testing CX-2009 in Neoplasms in 125 participants. Completed in 2 June 2023.

Timeline

29 December 2020

Primary endpoint
2 June 2023

2 June 2023

Quick facts

Lead sponsor	CytomX Therapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	125
Start date	29 December 2020
Primary completion	2 June 2023
Estimated completion	2 June 2023
Sites	42 locations across United States, Spain, South Korea

Drugs / interventions tested

CX-2009 — full drug profile →
CX-072 — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →
Breast Neoplasms — all drugs for Breast Neoplasms →
Breast Neoplasms, Triple-Negative — all drugs for Breast Neoplasms, Triple-Negative →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

CytomX Therapeutics — full company profile →

Who can join

18 and older, any sex, with Neoplasms or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
Triple negative breast cancer: Pitfalls and progress.
Zagami P, Carey LA. · · 2022 · cited 546× · PMID 35987766 · DOI 10.1038/s41523-022-00468-0
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.
Chen YF, Xu YY, Shao ZM, Yu KD. · · 2023 · cited 93× · PMID 36357174 · DOI 10.1002/cac2.12387
The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.
Sasso JM, Tenchov R, Bird R, Iyer KA, et al · · 2023 · cited 89× · PMID 37821099 · DOI 10.1021/acs.bioconjchem.3c00374
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Boni V, Fidler MJ, Arkenau HT, Spira A, et al · · 2022 · cited 50× · PMID 35165101 · DOI 10.1158/1078-0432.ccr-21-3656
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Exploiting protease activation for therapy.
Bleuez C, Koch WF, Urbach C, Hollfelder F, et al · · 2022 · cited 27× · PMID 35314338 · DOI 10.1016/j.drudis.2022.03.011

Verify or expand the search:

Other trials of CX-2009

Trials testing the same drug.

NCT03149549 — PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected So · Phase 1, PHASE2 · terminated

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other CytomX Therapeutics trials

Trials by the same sponsor.

NCT06462794 — First In Human Study of CX-801 in Advanced Solid Tumors · Phase 1 · recruiting
NCT06265688 — First In Human Study of CX-2051 in Advanced Solid Tumors · Phase 1 · recruiting
NCT05387265 — A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors · Phase 1 · terminated
NCT03993379 — PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults W · Phase 2 · terminated
NCT03543813 — PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumor · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04596150 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CytomX Therapeutics
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04596150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing